Every material Form 8-K Innospec filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Innospec reported third-quarter 2026 revenue of $473.6 million, up 7% from $441.9 million a year earlier, and net income attributable to Innospec of $31.8 million, or $1.29 per diluted share, versus $12.9 million, or $0.52, a year earlier. The Board declared a semi-annual dividend of $0.94 per share, bringing the annual dividend to $1.86, a 9% increase over 2025, which shareholders of record as of November 17, 2026 will receive on November 25, 2026.
Revenue of $473.6 million, up 7% from $441.9 million in the third quarter of 2025.
GAAP diluted EPS of $1.29 versus $0.52; adjusted non-GAAP EPS of $1.29 versus $1.12.
Semi-annual dividend of $0.94 per share, payable November 25, 2026; annual dividend of $1.86, up 9%.
Cash from operating activities of $17.4 million versus $39.1 million a year earlier; cash of $251.9 million and no debt as of September 30, 2026.
Innospec reported results for the quarter ended June 30, 2026, with revenue up 12% to $491.4 million and GAAP net income of $30.8 million, or $1.25 per diluted share, compared with $23.5 million, or 94 cents, a year earlier. Adjusted non-GAAP EPS was $1.27 versus $1.26, and the company ended the quarter with $250.2 million in cash and no debt. Operating cash flow was only $7.2 million for the quarter, and the filing does not include formal guidance.
Revenue of $491.4 million, up 12% from $439.7 million a year earlier
Net income attributable to Innospec of $30.8 million, or $1.25 per diluted share, versus $1.25 year over year and 94 cents in Q2 2025
Adjusted non-GAAP EPS of $1.27 versus $1.26; cash from operations of $7.2 million before $16.5 million capital expenditure
Net cash of $250.2 million with no debt; $6.4 million spent on share repurchases in the quarter
Innospec's board increased its size from seven to eight directors and appointed Shelley Bausch as a Class II director effective July 1, 2026, with a seat on the Audit Committee. The filing describes her standard non-employee director pay, which does not involve a change in company results or outlook.
Board increased from seven to eight directors, effective June 2, 2026
Shelley Bausch appointed Class II director starting July 1, 2026, serving until the 2027 annual meeting
Bausch joins the Audit Committee as of July 1, 2026; annual cash retainer of $100,000 plus $5,000 for Audit Committee service
Expected annual equity grant value of $125,000 in February each year
Innospec reported first-quarter 2026 revenue of $453.2 million, up 3% from a year earlier, but GAAP diluted EPS fell to $1.22 from $1.31 and adjusted EPS fell to $1.05 from $1.42, with Performance Chemicals hit by a January 2026 US winter storm. The Board raised the semi-annual dividend 10% to $0.92 per share and authorized a new $75 million share repurchase program starting May 12, 2026.
Revenue $453.2 million vs. $440.8 million; Performance Chemicals operating income fell 46% to $10.7 million
GAAP diluted EPS $1.22 vs. $1.31; adjusted non-GAAP EPS $1.05 vs. $1.42
Semi-annual dividend of $0.92 per share, up 10%, payable May 29, 2026 to holders of record May 19, 2026
New $75 million buyback over three years replaces the $50 million authorization, of which about $16 million remained
Innospec reported fourth quarter and full year 2025 results. Fourth quarter revenue fell 2% to $455.6 million, while GAAP net income rose to $47.4 million from a prior-year loss that included a UK pension settlement charge. Full-year revenue fell 4% to $1.78 billion and adjusted EBITDA fell 10% to $203.0 million, so the year's operating trend was weaker even though GAAP earnings improved.
Q4 GAAP net income of $47.4 million, or $1.91 per diluted share, versus a net loss of $70.4 million, or $2.80 per share, a year earlier
Q4 adjusted non-GAAP EPS of $1.50 versus $1.41 a year ago; full-year adjusted EPS of $5.27 versus $5.92 in 2024
Full-year adjusted EBITDA of $203.0 million, down 10% from $225.2 million; net cash of $292.5 million at December 31, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Innospec filing is on SEC EDGAR ↗. 8-K briefs of other companies →